Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS Neuronal Survival and mHTT Toxicity by Wertz, Mary H. et al.
Neuron, Volume 106Supplemental InformationGenome-wide In Vivo CNS Screening
Identiﬁes Genes that Modify CNS
Neuronal Survival and mHTT Toxicity
Mary H. Wertz, Mollie R. Mitchem, S. Sebastian Pineda, Lea J. Hachigian, Hyeseung
Lee, Vanessa Lau, Alex Powers, Ruth Kulicke, Gurrein K. Madan, Medina Colic, Martine
Therrien, Amanda Vernon, Victoria F. Beja-Glasser, Mudra Hegde, Fan Gao, Manolis
Kellis, Traver Hart, John G. Doench, and Myriam Heiman
Supplemental Information 
 
Figure S1.  Characterization of Lentiviral Spread and Estimation of in vivo Lentivirus 
Multiplicity of Infection, Related to Figure 1.   
 
Figure S2. Coverage and Performance of shRNA and sgRNA Pooled Libraries in vivo, Related 
to Figure 1.   
 
Figure S3. Comparison of Striatal-Enriched Genes and Core Essential Genes (CEG2) to 
Candidate Neuronal Essential Genes Identified in shRNA and CRISPR Screens, Related to 
Figures 2 and 3.   
 
Figure S4.  Identification of Candidate Protective and Vulnerability Factors in HD Mouse 
Models, Related to Figure 4. 
 
Figure S5. Levels of Nme1 Expression in Mouse and Human Brain, and Effects of Nme1 
knockdown and overexpression in vivo and in vitro, Related to Figure 5. 
  
1
-0.
30
-0.
20
-0.
100.0
0
0.1
0
0.2
0
0.2
6
0.3
8
0.5
0
0.6
0
0.7
2
0.8
6
0.9
8
1.1
0
1.2
0
0
10
20
30
40
Bregma (mm)
%
 o
f S
tria
tu
m
 G
FP
 P
os
itiv
e
-0.
30
-0.
20
-0.
100.0
0
0.1
0
0.2
0
0.2
6
0.3
8
0.5
0
0.6
0
0.7
2
0.8
6
0.9
8
1.1
0
1.2
0
0
500
1000
1500
2000
Bregma (mm)
GF
P+
 ce
lls
/til
ed
 im
ag
e
GFP+ Area
0
10
20
30
40
%
 o
f S
tria
tu
m
 G
FP
 P
os
itiv
e
Cell #
0
500
1000
1500
GF
P+
 ce
lls
/til
ed
 im
ag
e
Ou
tsi
de
 In
jec
tio
n 
   
  A
t I
nje
cti
on
 S
ite
Ou
tsi
de
 In
jec
tio
n 
   
  A
t I
nje
cti
on
 S
ite
Iba1        NeuN  DAPI        Merge
GFAP        NeuN  DAPI        Merge
At 
Inje
ctio
n S
ite
Ou
tsid
e In
jec
tion
0
2
4
6
8
10
Pe
rc
en
t  A
re
a 
Ib
a1
+
*
At 
Inje
ctio
n S
ite
Ou
tsid
e In
jec
tion
0
2
4
6
8
10
Pe
rc
en
t  A
re
a 
GF
AP
+ *
0-1
00
100
-20
0
200
-30
0
> 3
00
0
200
400
600
800
1000
1200
Distance from needle (um)
Flu
or
es
en
ce
 In
ten
sit
y
nu
m
Ge
ne
s
A       B     C
       D     E
F
       G              H
I                   J
K                   L
-6          -5           -4          -3           -2
  log10(shRNA abundance by gene)
2500
2000
1500
1000
500
0
Figure S1. Characterization of Lentiviral Spread and Estimation of in vivo Lentivirus 
Multiplicity of Infection, Related to Figure 1.  (A) Representative image of control, GFP cDNA 
lentiviral spread after injection into the adult striatum. Scale bar = 400µm.  (B) Area of the striatum 
(red line in panel A) positive for GFP viral infection (white line in panel A) was measured for each 
section from anterior to posterior across the injection sites.  The percent GFP-positive area present 
in 4 serial coronal sections is represented as mean and standard deviation (SD) for each coordinate 
relative to Bregma (mm).  (C) The GFP positive area (effective viral coverage) across the injection 
sites is 26.41% of the striatum, n = 60 sections.  (D) GFP positive cells were manually counted in 
maximum intensity projections of serial 20x 10µm Z-stacks of the GFP positive injection area.  
The number of GFP positive cells for 4 serial sections is represented as mean + SD for each 
coordinate relative to Bregma (mm).  (E) Bar graph of the average number of GFP-positive cells 
per 10µm Z-stack of a 20µm section, n = 56 sections. Together the viral spread and number of 
cells counted per 10µm section indicate ~120,000 neurons are infected per striatal hemisphere (see 
STAR Methods for details).  Bars represent mean + SD.  (F) Representative image of endogenous 
fluorescence intensity of GFP-positive cells in a tissue section directly adjacent to the injection 
site (red box) vs. at the periphery of the injection (yellow box).  Scale bar = 50µm.  (G) Endogenous 
fluorescence intensity of individual cells was measured from summed intensity projections of tiled 
20µm Z-stacks to evaluate in vivo MOI.  Median fluorescence intensity in arbitrary units at the 
periphery is 65.32, while at the needle track is 371.00, indicating a 5.68-fold range in the 
distribution of viral integration events.  n > 165 cells per distance bin from 4 coronal sections, bars 
represent median value. (H) Histogram of the distribution of log10 shRNA read counts by gene in 
the input library shows the relative abundance of the total shRNA targeting each gene.  (I) Iba1, 
and (K) GFAP co-stained with NeuN and DAPI in virus-injected striatum of C57Bl/6J control 
mice.  40x z-stack images were taken at the center of the injection site and compared to a region 
peripheral to the injection site. (J/L) Quantification of Iba1 and GFAP staining showed a small 
localized increase in inflammatory markers adjacent to the center of the injection site, but not 
peripheral to the injection, n = 3, * p-value < 0.05; two-tailed student’s t-test.  Images have been 
modified to increase contrast for visualization purposes. All images were modified identically and 
quantification was performed on unmodified images as described in the methods.  
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Figure S2. Coverage and Performance of shRNA and sgRNA Pooled Libraries in vivo, 
Related to Figure 1.  (A) Representative scatterplots of the log2 normalized read counts in libraries 
of low to high complexity (1,000; 3,100; 20,000; and 92,000 elements).  Pooling higher numbers 
of samples (1, 5, 10, 20, and 37) into a single replicate reduces variation and increases the Pearson 
correlation coefficient (r) as shown for each comparison.  A single replicate is sufficient for full 
coverage and high correlation (r > 0.75) of small 1,000 and 3,100 element libraries, while pooling 
of many samples per replicate is required for the 20,000 and 92,000 element libraries.  (B) 
Cumulative density function (CDF) plot of the cumulative frequency vs. the log2 normalized 
representation of shRNAs in the genome-wide library. The WT control replicates both 4 weeks 
(blue) and 7 months (orange) of in vivo incubation are similar to the plasmid input (black).  (C) 
Boxplot of the distributions of log2 normalized read counts in the shRNA screening data sets as 
compared to the plasmid input.  (D) CDF plot of the cumulative frequency vs. the log2 normalized 
representation of sgRNAs in the input library (black) and the WT 4 weeks samples (orange).  (E) 
Boxplot of the distributions of log2 normalized read counts in the sgRNA screening data sets as 
compared to the plasmid input.  Together these plots illustrate recovery of the library at a depth 
sufficient for analysis of differential library representation in the pooled replicate samples.   
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Figure S3. Comparison of Striatal-Enriched Genes and Core Essential Genes (CEG2) to 
Candidate Neuronal Essential Genes Identified in shRNA and CRISPR Screens, Related to 
Figures 2 and 3.  (A) Venn diagram of overlap between striatal enriched genes [>1.5 log2 fold-
change enrichment in striatum vs. rest of brain (Kasukawa et al., 2011)] and neuronal essential 
genes identified in the WT shRNA screen.  (B) ChEA analysis of the 72 neuronal essential genes 
which display > 1.5 log2 fold-change striatal enriched expression (overlap in panel A, and listed in 
Table S2), to identify putative regulators of these genes from published chromatin 
immunoprecipitation studies.  Results represented as Fisher’s exact test –log10 p-value.  (C) 
Heatmap of the top 15 candidate neuronal essential genes with enriched expression in the striatum 
vs. the rest of the brain (left column, fold enrichment in striatum).  All of these genes have 
significantly decreased expression (corrected p-value < 0.05) in the striatum of the either the R6/2 
or zQ175 HD mouse models, or both (right two columns, fold downregulation in HD model).  (D) 
Density plot of normZ scores for the WT CRISPR screen shows normal distribution.  (E) Venn 
diagram of the overlap of neuronal essential genes identified by both the shRNA and CRISPR 
sgRNA screens, hypergeometric p-value = 0.023.  
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Figure S4. Identification of Candidate Protective and Vulnerability Factors in HD Mouse 
Models, Related to Figure 4.  (A and B) Scatterplots (corresponding to Figure 4B and 4D) 
illustrating the correlation of log2 normalized read counts in the R6/2 and zQ175 screens 
respectively.  Points represent individual shRNA hairpins enriched (red) or depleted (blue) with > 
2-fold differential shRNA sequencing representation in the mutant as compared to the isogenic
WT control.  Highly correlated sequences with a log2 normalized value greater than 8 are shRNAs
that are highly represented in the library, but are not differentially recovered in the screen.  (C and
D) Top KEGG pathways significantly associated with candidate essential genes (knockdown is
harmful, library elements are depleted as described in the main text) unique to either the R6/2 (red)
and zQ175 (orange) screens respectively, and not identified as essential in the WT neuronal
essential shRNA screen, represented with Fisher’s exact test –log10 p-value.  Even though these
genes were not identified as essential in the WT neuronal essential shRNA screen, there was still
pathway overlap evident with WT neuronal essential genes (green).  (E and F) Plot of normZ
scores vs. rank of candidate mHTT vulnerability factors (knockdown is protective, library
elements in this case are enriched) identified by DrugZ.  The top genes from each arm of the screen
are labeled in purple.  Top (G and I) KEGG pathways and (H and J) GO terms significantly
associated with candidate vulnerability factors in the R6/2 and zQ175 screens respectively,
Fisher’s exact test expressed as –log10 p-value.  Pathways overlapping between the R6/2 and
zQ175 screens are marked with an *.
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Figure S5. Levels of Nme1 expression in mouse and human brain, and effects of Nme1 
knockdown and overexpression in vivo and in vitro, Related to Figure 5.  (A) qRT-PCR of 
Nme1 mRNA expression in WT mouse brain regions normalized to Actb shows lowest expression 
of Nme1 in striatum, n = 3 biological replicates.  Ordinary one-way ANOVA **** P < 0.0001, 
Tukey’s multiple comparison test * p = 0.027, ** p = 0.003, *** p = 0.0003, **** p < 0.0001.  (B) 
Multiplex Taqman qRT-PCR analysis of a human cDNA array (Origene) confirms low expression 
of NME1 (normalized to ACTB) in the caudate, putamen, and nucleus accumbens (blue) as 
compared to overall human brain expression; n = 1 array.  (C) Enriched expression of DARPP-32 
(PPP1R1B) in the caudate and putamen (normalized to ACTB) in the human cDNA array confirms 
the specificity of the array panel; n = 3 arrays.  (D) 10x tiled image of a representative GFP AAV9 
viral spread area in the striatum upon stereotaxic intracranial injection (Scale bar = 300µm). 
Contrast in GFP and DAPI images was increased for visualization purposes.  (E) qPCR 
quantification of the relative fold-change of Nme1 mRNA expression in the Nme1 KD2 as 
compared to Control KD injected hemispheres to confirm knockdown with a second Nme1 shRNA 
hairpin sequence, n = 10, ** = p-value = 0.0097, * p-value = 0.013; one-tailed, paired student’s t-
test of DeltaCt values.  (F) Quantification of NeuN-positive cells in the Control KD vs. Nme1 KD2 
injected striatal hemispheres of WT (n = 4) and R6/2 (n=3) mice.  Points are an average of three 
images per section from 8 or 16 sections; one-tailed, paired t-test, p-value = 0.01.  (G) Effect of 
striatal Control OX on the body weights of WT or R6/2 HD model mice.  Two-way repeated 
measures ANOVA p-value genotype <0.0001 with Sidak’s, multiple comparison test, * p = 0.013, 
** p = 0.0046, *** p = 0.0006, **** P < 0.00001.  (H) Effect of striatal Nme1 OX on body weight 
of WT vs. R6/2 HD model mice. Two-way repeated measures ANOVA with Sidak’s multiple 
comparison test, ** p = 0.0013, and **** P < 0.0001.  (I) Effect of striatal Control OX or striatal 
Nme1 OX on the arousability (at 9 weeks of age, 4 weeks after viral transduction) of WT or R6/2 
HD model mice.  Two-way repeated measures ANOVA p-value genotype = 0.017 with Sidak’s, 
multiple comparison test, **** p-value <0.0001 WT Control OX and WT Nme1 OX vs. R6/2 
Control OX. (J) ACTIONet graphs of the major annotated cell types in the R6/2 model of HD (n 
= 95,885 nuclei across 20 mice: 5 WT and 5 R6/2 model mice, each for Control and Nme1 OX).  
(K) Quantification of EM48+ puncta size in Control KD vs. Nme1 KD injected hemispheres of 
R6/2 mice (n = 3).  (L and M) Quantification of mHTT aggregates as normalized EM48+ puncta 
per image and size of EM48+ puncta in Control KD vs. Nme1 KD2 injected hemispheres of R6/2 
11
mice (n = 3).  Panels K-M, points are an average of three images per section from 16 sections, 
**** p-value < 0.0001; one-tailed paired student’s t-test.  (N) Quantification of EM48+ puncta 
size in Control OX vs. Nme1 OX injected hemispheres of R6/2 mice (n = 4).  Points are an average 
of three images per section from 8 sections; n.s. one-tailed paired student’s t-test. All error bars 
represent mean and +/- SEM. 
12
